N-(叔丁氧羰基)-L-鸟氨酸叔丁酯盐酸盐 | 214629-97-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(叔丁氧羰基)-L-鸟氨酸叔丁酯盐酸盐
• 中文别名: Boc-鸟氨酸-叔丁酯盐酸盐
• 英文名称: Boc-Orn-O-t-Bu*HCl
• 英文别名: N-α-tert-butyloxycarbonyl-L-ornithinetert-butyl ester hydrochloride；Boc-Orn(H)-OtBu*HCl；Boc-Orn-OtBu hydrochloride；Boc-Orn(NH₃Cl)-OtBu；N^α-Boc-L-ornithine tert-butyl ester hydrochloride；(N_α-Boc)-Orn tert-butyl ester；(S)-tert-Butyl 5-amino-2-((tert-butoxycarbonyl)amino)pentanoate hydrochloride；tert-butyl (2S)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate;hydrochloride
• CAS: 214629-97-7
• 化学式: C₁₄H₂₈N₂O₄*ClH
• 分子量: 324.848
• InChiKey: QAOZFDDKCLTTAV-PPHPATTJSA-N

物化性质

• 溶解度：
  甲醇（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(叔丁氧羰基)-L-鸟氨酸叔丁酯盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 90.0h， 生成 tert-butyl (2S)-6-[1-[(2,4-dimethoxyphenyl)methyl]-2-[[(4S)-5-[(2-methylpropan-2-yl)oxy]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentyl]amino]imidazo[4,5-b]pyridin-4-ium-4-yl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate;iodide
  参考文献：
  名称：

  Total Synthesis of Pentosidine

  摘要：

  Pentosidine, a biologically important advanced glycation endproduct, has been accessed in a rapid, high-yielding manner. The synthesis was accomplished via a six-step sequence starting with 3-amino-2-chloropyridine and features a palladium-catalyzed tandem cross-coupling/cyclization to construct the imidazo[4,5-b]pyridine core.

  DOI：

  10.1021/ol3021226
• 作为产物：
  描述：

  N^α-(tert-butyloxycarbonyl)-N^δ-(benzyloxycarbonyl)-L-ornithine tert-butyl ester 在 盐酸 、 5% Pd/C 、 水 、 氢气 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以98%的产率得到N-(叔丁氧羰基)-L-鸟氨酸叔丁酯盐酸盐
  参考文献：
  名称：

  Total Synthesis of Pentosidine

  摘要：

  Pentosidine, a biologically important advanced glycation endproduct, has been accessed in a rapid, high-yielding manner. The synthesis was accomplished via a six-step sequence starting with 3-amino-2-chloropyridine and features a palladium-catalyzed tandem cross-coupling/cyclization to construct the imidazo[4,5-b]pyridine core.

  DOI：

  10.1021/ol3021226

文献信息

• [EN] NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR TGR5 SOUS FORME D'HÉTÉROARYLES BICYCLIQUES CONTENANT DE L'AZOTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012149236A1

  公开（公告）日：2012-11-01

  Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  公式I的新化合物：或其对映体、二对映体、互变异构体、前药或盐，其中m、Q、T、U、V、环A、X、Y、R3、R4、R4a、R5a、R5b、R5c、R5d、R5e、R6a、R6b和R6c在此定义，提供了TGR5 G蛋白偶联受体调节剂。TGR5 G蛋白偶联受体调节剂在治疗、预防或减缓需要TGR5 G蛋白偶联受体调节剂治疗的疾病的进展方面是有用的。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这类新化合物的组合物治疗与TGR5 G蛋白偶联受体活性相关的疾病或症状的方法。
• Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells
  作者：Adrien Chouchou、Cindy Patinote、Pierre Cuq、Pierre-Antoine Bonnet、Carine Deleuze-Masquéfa

  DOI：10.3390/molecules23112987

  日期：——

  Imiqualines (imidazoquinoxaline derivatives) are anticancer compounds with high cytotoxic activities on melanoma cell lines. The first generation of imiqualines, with two lead compounds (EAPB0203 and EAPB0503), shows remarkable in vitro (IC50 = 1 570 nM and IC50 = 200 nM, respectively, on the A375 melanoma cell line) and in vivo activity on melanoma xenografts. The second generation derivatives, EAPB02302 and EAPB02303, are more active, with IC50 = 60 nM and IC50 = 10 nM, respectively, on A375 melanoma cell line. The aim of this study was to optimize the bioavailability of imiqualine derivatives, without losing their intrinsic activity. For that, we achieved chemical modulation on the second generation of imiqualines by conjugating amino acids on position 4. A new series of twenty-five compounds was efficiently synthesized by using microwave assistance and tested for its activity on the A375 cell line. In the new series, compounds 11a, 9d and 11b show cytotoxic activities less than second generation compounds, but similar to that of the first generation ones (IC50 = 403 nM, IC50 = 128 nM and IC50 = 584 nM, respectively). The presence of an amino acid leads to significant enhancement of the water solubility for improved drugability.

  伊米奎林（咪唑喹喔啉衍生物）是一类抗癌化合物，对黑色素瘤细胞系具有高细胞毒活性。第一代伊米奎林具有两种主要化合物（EAPB0203和EAPB0503），在黑色素瘤细胞系中显示出显著的体外活性（IC50分别为1570纳摩尔和200纳摩尔），并对黑色素瘤异种移植瘤具有体内活性。第二代衍生物EAPB02302和EAPB02303更为活跃，在A375黑色素瘤细胞系中的IC50分别为60纳摩尔和10纳摩尔。本研究的目的是优化伊米奎林衍生物的生物利用度，同时不损失其固有活性。为此，我们通过在第二代伊米奎林上连接氨基酸在位置4上进行化学调制。利用微波辅助有效合成了一系列新的二十五个化合物，并对其在A375细胞系上的活性进行了测试。在新系列中，11a、9d和11b化合物的细胞毒活性低于第二代化合物，但类似于第一代（IC50分别为403纳摩尔、128纳摩尔和584纳摩尔）。氨基酸的存在显著提高了水溶性，从而提高了药物可用性。
• Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1
  作者：Sara Tommasi、Chiara Zanato、Benjamin C. Lewis、Pramod C. Nair、Sergio Dall'Angelo、Matteo Zanda、Arduino A. Mangoni

  DOI：10.1039/c5ob01843a

  日期：——

  and synthesis of 12 novel DDAH-1 inhibitors and report their derived kinetic parameters, IC50 and Ki. Arginine analogue 10a, characterized by an acylsulfonamide isosteric replacement of the carboxylate, showed a 13-fold greater inhibitory potential relative to the known DDAH-1 inhibitor, L-257. Compound 10a was utilized to study the putative binding interactions of human DDAH-1 inhibition using molecular

  二甲基精氨酸二甲基氨基水解酶（DDAH）是参与不对称二甲基精氨酸（ADMA）和N-单甲基精氨酸（NMMA）代谢的关键酶，它们是一氧化氮合酶（NOS）家族的内源抑制剂。在人类中已鉴定出两种DDAH亚型，即DDAH-1和DDAH-2。DDAH-1抑制代表了一种有希望的策略，它可以限制病理状态下NO的过量产生而又不影响这一重要信使分子的稳态作用。在这里，我们描述了12种新型DDAH-1抑制剂的设计和合成，并报告了其衍生的动力学参数IC 50和K i。精氨酸类似物10a的特征在于羧酸的酰基磺酰胺等位替代，相对于已知的DDAH-1抑制剂L-257，其抑制潜力高13倍。使用分子动力学模拟，化合物10a用于研究人DDAH-1抑制作用的推定结合相互作用。后者表明在DDAH-1活性位点中发生了几种稳定相互作用，从而为体外抑制研究证明了增强的抑制潜力提供了结构上的见识。
• A novel method for screening peptides that bind to proteins by using multiple fluorescent amino acids as fluorescent tags
  作者：Mizuki Kitamatsu、Midori Futami、Masahiko Sisido

  DOI：10.1039/b920426a

  日期：——

  We describe a new screening method for simultaneously detecting peptides that bind to a target protein by fluorescence obtained from fluorescent amino acid-modified peptides.

  我们介绍了一种新的筛选方法，可通过荧光氨基酸修饰肽获得的荧光同时检测与目标蛋白质结合的肽。
• Ritter-based glycoconjugation of amino acids and peptides—access to novel glycoconjugates displaying a β-amide linkage between amino acid and sugar moiety
  作者：Marlin Penner、Frank Schweizer

  DOI：10.1016/j.carres.2006.11.006

  日期：2007.1

  Beta-peptidic-D-gluco-, D-galacto-, and L-fuco-configured glycosyl amino acids can be prepared from the corresponding 2-deoxy-oct-3-ulopyranosonic acids via a one-pot intramolecular Ritter reaction. Initially, a ketopyranoside-based acid condenses under Lewis acid promoted conditions with nitriles (PhCN, MeCN) and a partially protected diamino ester (Boc-DAB-O-t-Bu, Boc-Orn-O-t-Bu) to form a beta-peptidic

  β-肽-D-葡萄糖-，D-半乳糖和L-fuco-构型的糖基氨基酸可以通过一锅内分子Ritter反应由相应的2-deoxy-oct-3-ulopyranosonic酸制备。最初，基于酮吡喃糖苷的酸在路易斯酸促进的条件下与腈（PhCN，MeCN）和部分受保护的二氨基酯（Boc-DAB-Ot-Bu，Boc-Orn-Ot-Bu）缩合形成β-肽糖基氨基叔丁基酯。糖基氨基叔丁基酯可以被转化为Fmoc保护的糖基氨基酸，其被适当地保护用于固相糖肽合成。此外，用固定的肽胺代替被保护的二氨基酯允许在固相上肽的合成后的N-末端和N（ε）-糖缀合。